ReviewProtoplasma2026
Probiotics as modulators of the gut-derived incretin peptide axis in type 2 diabetes: GLP-1, GLP-2, and microbial metabolite signaling.
Review in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to examine the role of probiotics in modulating the gut-derived incretin peptide axis in type 2 diabetes (T2D), with emphasis on GLP-1, related gut peptides such as GLP-2, microbial metabolite signaling, and both conventional and engineered probiotic approaches. Narrative synthesis of literature from PubMed, Scopus, and Google Scholar, using search terms such as 'probiotics', 'GLP-1', 'type 2 diabetes', and 'gut microbiota'. Recent literature from 2015 to 2025 was prioritized, including randomized controlled trials, meta-analyses, systematic reviews, and relevant preclinical studies. Earlier landmark studies were included only when they established foundational mechanisms related to incretin biology, SCFA-FFAR signaling, or GLP-1 secretion physiology. Probiotics promote GLP-1 secretion via SCFAs binding to FFAR2/3 receptors, leading to improved glycemic control in meta-analyses, though with heterogeneity. Engineered probiotics like LgsGPA show superior preclinical efficacy in alleviating hyperglycemia and restoring β-cell function. While conventional probiotics offer benefits, engineered systems represent a promising advancement, requiring further clinical and regulatory development for personalized T2D therapy.
Indexed as
Identifiers
42373794What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.